View Filing Data

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Jun. 30, 2016	Aug. 03, 2016
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Trading Symbol	hsm
Entity Registrant Name	HELIUS MEDICAL TECHNOLOGIES, INC.
Entity Central Index Key	0001610853
Current Fiscal Year End Date	--03-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		84,324,684
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2016	Mar. 31, 2016
Current assets
Cash and cash equivalents	$ 7,973,437	$ 2,643,937
Receivables	532,359	399,106
Prepaid expenses	590,355	502,264
Other current assets	0	495,415
Total current assets	9,096,151	4,040,722
TOTAL ASSETS	9,096,151	4,040,722
Current liabilities
Accounts payable and accrued liabilities	1,036,766	2,181,154
Shares to be issued	0	150,000
Derivative liability	3,303,277	1,725,760
Total current liabilities	4,340,043	4,056,914
TOTAL LIABILITIES	4,340,043	4,056,914
Commitments and contingencies
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock (Unlimited Class A common shares authorized); (84,323,934 shares issued and outstanding at June 30, 2016 and 72,193,209 shares issued and outstanding at March 31, 2016)	30,569,600	24,347,930
Additional paid-in capital	4,669,135	2,940,539
Accumulated other comprehensive loss	(1,092,940)	(999,398)
Accumulated deficit	(29,389,687)	(26,305,263)
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)	4,756,108	(16,192)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 9,096,151	$ 4,040,722

Condensed Consolidated Balance Sheets (Parenthetical) - shares	Jun. 30, 2016	Mar. 31, 2016
Common Stock, Shares Authorized
Common Stock, Shares, Issued	84,323,934	72,193,209
Common Stock, Shares, Outstanding	84,323,934	72,193,209

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Operating Expenses
General and administrative	$ 1,449,981	$ 1,464,849
Research and development	653,883	1,520,824
Total operating expenses	2,103,864	2,985,673
Loss from operations	(2,103,864)	(2,985,673)
Other Income (expense)
Interest expense, net	0	(53)
Other income	109,500	0
Change in fair value of derivative liability	(1,309,382)	512,784
Foreign exchange gain (loss)	219,322	(81,425)
Total other income (expense)	(980,560)	431,306
Net loss	(3,084,424)	(2,554,367)
Other comprehensive income (loss)
Foreign currency translation adjustments	(93,542)	40,626
Comprehensive loss	$ (3,177,966)	$ (2,513,741)
Net loss per share
Basic and dilutive	$ (0.04)	$ (0.04)
Weighted average shares outstanding
Basic and dilutive	81,003,020	63,722,378

Condensed Consolidated Statements of Stockholders Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Shares to be Issued [Member]	Accumulated Deficit [Member]	Accumulated other comprehensive income (loss)[Member]	Total
Beginning Balance at Mar. 31, 2015	$ 16,358,093	$ 2,434,552	$ 39,545	$ (19,423,451)	$ (971,640)	$ (1,562,901)
Beginning Balance (Shares) at Mar. 31, 2015	63,104,788
Exercise of finders warrants	$ 11,926					11,926
Exercise of finders warrants (Shares)	14,400
Issuance of common stock for private placement	$ 1,465,524					1,465,524
Issuance of common stock for private placement (Shares)	849,273
Issuance of common stock for private placement 2	$ 585,702		$ (39,545)			546,157
Issuance of common stock for private placement 2 (Shares)	335,463
Share issuance cost	$ (124,877)					(124,877)
Stock-based compensation on 2,970,000 options granted		174,676				174,676
Stock-based compensation on 400,000 options granted		285,462				285,462
Fair value of non-employee vested options reallocated to derivative liability		(690,885)				(690,885)
Net loss for the period				(2,554,367)		(2,554,367)
Translation adjustments					40,626	40,626
Ending Balance at Jun. 30, 2015	$ 18,296,368	2,203,805		(21,977,818)	(931,014)	(2,408,659)
Ending Balance (Shares) at Jun. 30, 2015	64,303,924
Beginning Balance at Mar. 31, 2016	$ 24,347,930	2,940,539		(26,305,263)	(999,398)	(16,192)
Beginning Balance (Shares) at Mar. 31, 2016	72,193,209
Exercise of finders warrants	$ 1,548,863	(151,184)				1,397,679
Exercise of finders warrants (Shares)	1,825,600
Issuance of common stock in public offering	$ 6,547,997					6,547,997
Issuance of common stock in public offering (Shares)	10,305,125
Issuance of warrants in public offering		1,504,914				1,504,914
Share issuance cost	$ (1,875,190)	366,271				(1,508,919)
Stock-based compensation on 3,370,000 options granted		195,987				195,987
Stock-based compensation on 400,000 options granted		37,831				37,831
Stock-based compensation on 100,000 options granted 1		8,455				8,455
Stock-based compensation on 100,000 options granted 2		9,126				9,126
Stock-based compensation on 50,000 options granted		1,248				1,248
Stock-based compensation on 750,000 options granted		13,070				13,070
Stock-based compensation on 950,000 options granted		7,807				7,807
Stock-based compensation on 100,000 options granted 3		3,206				3,206
Fair value of non-employee vested options reallocated to derivative liability		(268,135)				(268,135)
Net loss for the period				(3,084,424)		(3,084,424)
Translation adjustments					(93,542)	(93,542)
Ending Balance at Jun. 30, 2016	$ 30,569,600	$ 4,669,135		$ (29,389,687)	$ (1,092,940)	$ 4,756,108
Ending Balance (Shares) at Jun. 30, 2016	84,323,934

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities
Net loss	$ (3,084,424)	$ (2,554,367)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of derivative liability	1,309,382	(512,784)
Stock-based compensation	276,730	460,138
Unrealized foreign exchange loss	0	115,638
Changes in operating assets and liabilities:
Receivables	(133,253)	(15,264)
Prepaids and other current assets	(88,091)	(22,205)
Accounts payable and accrued liabilities	(648,973)	382,844
Net cash used in operating activities	(2,368,629)	(2,146,000)
Cash flows from investing activities
Proceeds from the sale of short term investment	0	378,000
Net cash provided by investing activities	0	378,000
Cash flows from financing activities
Proceeds from the issuance of common stock and warrants	7,902,912	2,519,561
Share issue costs	(1,508,919)	(124,877)
Proceeds from exercise of warrants	1,397,679	0
Net cash provided by financing activities	7,791,672	2,394,684
Effect of foreign exchange rate changes on cash	(93,543)	(73,714)
Net change in cash and cash equivalents	5,329,500	552,970
Cash and cash equivalents, beginning of the period	2,643,937	418,893
Cash and cash equivalents, end of the period	7,973,437	971,863
Supplemental cash flow information
Interest paid in cash	0	0
Income taxes paid in cash	$ 0	$ 0

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

3 Months Ended

Jun. 30, 2016

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION [Text Block]

1.	DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

Helius Medical Technologies, Inc. (the “Company”) is engaged primarily in the medical technology industry focused on neurological wellness. The Company’s planned principal operations include the development, licensing and acquisition of unique and non-invasive platform technologies to amplify the brain’s ability to heal itself. To date the Company has not generated any revenue.

The Company was incorporated in British Columbia, Canada, on March 13, 2014. On May 28, 2014, the Company completed a continuation via a plan of arrangement whereby the Company moved from being a corporation governed by the British Columbia Corporations Act to a corporation governed by the Wyoming Business Corporations Act. The Company’s head office is located in Newtown, Pennsylvania.

The Company has two wholly-owned subsidiaries, Neurohabilitation Corporation (“Neuro”) and Helius Medical Technologies (Canada), Inc. (“Helius Canada”).

The Company is currently listed on the Toronto Stock Exchange (the “TSX”). The Company began trading on the Canadian Securities Exchange on June 23, 2014, under the ticker symbol “HSM”, and subsequently moved to the TSX on April 18, 2016. The Company also began trading on the OTCQB under the ticker symbol “HSDT” on February 10, 2015. The financial information is presented in United States Dollars.

Going Concern

The Company’s condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. The Company has incurred a net loss of $3,084,424 for the three months ended June 30, 2016 and, as of June 30, 2016, the Company has an accumulated deficit of $29,389,687. The Company has not generated any product revenues and has not achieved profitable operations. Until the Company generates a level of revenue to support its cost structure, the Company expects to continue to incur substantial operating losses and net cash outflows. There is no assurance that profitable operations will ever be achieved, and, if achieved, will be sustained on a continuing basis.

While the Company had cash and cash equivalents of $7,973,437 as of June 30, 2016, management does not believe these resources will be sufficient to meet the Company’s operating and capital needs through the end of its fiscal year ended March 31, 2017.

The Company intends to fund ongoing activities by utilizing current cash and cash equivalents and by raising additional capital through equity or debt financings. There can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, the Company may be compelled to reduce the scope of its operations and planned capital expenditure or sell certain assets, including intellectual property assets. This material uncertainty gives rise to substantial doubt about the Company’s ability to continue as a going concern.

Revision of Prior Period Financial Statements

In the fourth quarter of fiscal year 2016, the Company revised and corrected the accounting for stock compensation expense related to certain non-employee awards for prior interim periods in fiscal year 2016. The Company evaluated the materiality of this revision and concluded that it was not material to any of the previously issued financial statements. However, had this not been revised, the accounting may have resulted in a material misstatement to the financial statements for the full year fiscal 2016. Accordingly, the Company revised previously reported periods included in Form 10-Q for the quarters ended June 30, 2015 and December 31, 2015. The Company will revise all other previously reported periods as such financial information is included in future filings.

The effects of this revision on the Company’s Condensed Consolidated Statements of Equity and Operations and Comprehensive Loss were as follows:

		Three Months Ended June 30, 2015
		As Previously						As
		Reported			Adjustment			Revised
Additional paid-in capital	$	2,053,907		$	149,898		$	2,203,805
Research & development	$	1,370,926		$	149,898		$	1,520,824
Loss from operations	$	(2,835,775	)	$	(149,898	)	$	(2,985,673	)
Net loss	$	(2,404,469	)	$	(149,898	)	$	(2,554,367	)
Earnings per share
Basic and Diluted	$	(0.04	)	$	-		$	(0.04	)
Total comprehensive loss	$	(2,363,843	)	$	(149,898	)	$	(2,513,741	)

SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Jun. 30, 2016

SIGNIFICANT ACCOUNTING POLICIES [Text Block]

2.	SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed consolidated financial statements of Helius Medical Technologies, Inc. are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, applicable to interim periods and, in the opinion of management, include all normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. Our condensed consolidated financial statements have also been prepared on a basis substantially consistent with, and should be read in conjunction with, our audited consolidated financial statements for the year ended March 31, 2016, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission, or SEC, on June 28, 2016. The year-end condensed consolidated balance sheet data was derived from our audited financial statements, but does not include all disclosures required by GAAP. The results of our operations for any interim period are not necessarily indicative of the results of our operations for any other interim period or for a full fiscal year.

The accompanying condensed consolidated financial statements reflect the operations of Helius Medical Technologies, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Use of Estimates

The preparation of the consolidated financial statements in accordance with U.S. Generally Accepted Accounting Principles (“ U.S. GAAP” requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Significant estimates include the assumptions used in the fair value pricing model for share-based payment transactions and deferred income tax asset valuation allowances. Financial statements include estimates which, by their nature, are uncertain. Actual outcomes could differ from these estimates.

Principles of Consolidation

In the opinion of management, the accompanying unaudited financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s interim financial information.

Cash and Cash Equivalents

Cash and cash equivalents comprise cash at banks and on hand, and short-term highly liquid investments that have an insignificant interest rate risk and an original maturity of 3 months or less.

Concentrations of Credit Risk

The Company is subject to credit risk in respect of its cash. Amounts invested in such instruments are limited by credit rating, maturity, industry group, investment type and issuer. The Company is not currently exposed to any significant concentrations of credit risk from these financial instruments. The Company seeks to maintain safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements and a competitive after-tax rate of return.

Receivables

Accounts receivable are stated at their net realizable value. At June 30, 2016, the accounts receivable balance consisted primarily of GST and QST refunds as well as reimbursements from the US army related to the Company’s expenditures.

Stock-Based Compensation

The Company accounts for all stock-based payments and awards under the fair value based method. The Company recognizes its stock-based compensation using the straight line method.

Stock-based payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if the Company had paid cash instead of paying with or using equity based instruments. The fair value of the stock-based payments to non-employees that are fully vested and non-forfeitable as at the grant date are measured and recognized at that date.

The Company accounts for the granting of share purchase options to employees using the fair value method whereby all awards to employees will be measured at fair value on the date of the grant. The fair value of all share purchase options are expensed over their vesting period with a corresponding increase to additional capital surplus. Upon exercise of share purchase options, the consideration paid by the option holder, together with the amount previously recognized in additional paid-in capital is recorded as an increase to share capital. Share purchase options granted to employees are accounted for as liabilities when they contain conditions or other features that are indexed to other than a market, performance or service condition.

The Company uses the Black-Scholes option pricing model to calculate the fair value of share purchase options. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend yield of the common stock. Changes in these assumptions can materially affect the fair value estimate.

Foreign Exchange

The functional currency of the Company and Helius Canada is the Canadian dollar (“CAD”) and the functional currency of Neuro is the U.S. dollar (“USD”). The Company’s reporting currency is the U.S. dollar. Transactions in foreign currencies are remeasured into the functional currency of the relevant subsidiary at the exchange rate in effect at the date of the transaction. Any monetary assets and liabilities arising from these transactions are translated into the functional currency at exchange rates in effect at the balance sheet date or on settlement. Resulting gains and losses are recorded in other foreign exchange gain (loss) within the condensed consolidated statements of operations. The foreign exchange adjustment in the books of Neuro relating to inter-company advances from Helius that are denominated in Canadian dollars is recorded in the condensed consolidated statements of operations and comprehensive loss.

For the three months ended June 30, 2016, there was a foreign exchange gain of $219,322 and for the three months ended June 30, 2015 there was a foreign exchange loss of $81,425 recognized in the condensed consolidated statements of operations and comprehensive loss.

Income Taxes

The Company accounts for income taxes using the asset and liability method. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized.

The Company has adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 Income Taxes regarding accounting for uncertainty in income taxes. The Company initially recognizes tax provisions in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially and subsequently measured as the largest amount of the tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts. Application requires numerous estimates based on available information. The Company considers many factors when evaluating and estimating its tax positions and tax benefits. These periodic adjustments may have a material impact on the consolidated statements of operations and comprehensive loss. When applicable, the Company classifies penalties and interest associated with uncertain tax positions as a component of income tax expense in its consolidated statements of operations and comprehensive loss.

Research and Development Expenses

Research and development (“R&D”) expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations and materials and supplies. R&D costs are charged to operations when they are incurred.

Segment Information

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company, through its chief operating decision maker, views its operations and manages the business in one segment.

Derivative Liabilities

The Company evaluates its financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815 Derivatives and Hedging . The result of this accounting treatment is that the fair value of the derivative is marked-to-market at each balance sheet date and recorded as a liability and the change in fair value is recorded in the consolidated statements of operations and comprehensive loss. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.

The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instruments that become subject to reclassification are reclassified at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not settlement of the derivative instrument is expected within 12 months of the consolidated balance sheet date.

Fair Value Measurements

The Company’s financial instruments consist primarily of cash and cash equivalents, receivables, and accounts payable and accrued liabilities. The book values of these instruments approximate their fair values due to the immediate or short-term nature of those instruments.

ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The Company had certain Level 3 derivative liabilities required to be recorded at fair value on a recurring basis in accordance with U.S. GAAP as at June 30, 2016 and 2015. Unobservable inputs used in the valuation of these liabilities includes volatility of the underlying share price and the expected term. See Note 3. for the inputs used in the Black Scholes model at June 30, 2016 and the rollforward of the warrant liability and see Note 4. for the inputs used in the Black Scholes model at June 30, 2016 and 2015 for the rollforward of the derivative liability for non-employee options.

	Fair Value	Level 1	Level 2	Level 3
June 30, 2016

Liabilities:
Non-employee options	1,188,770	-	-	1,188,770
Warrants	2,114,507	-	-	2,114,507

March 31, 2016

Liabilities:
Non-employee options	521,179	-	-	521,179
Warrants	1,204,581	-	-	1,204,581

There were no transfers between any of the levels during the three months ended June 30, 2016 and 2015.

Basic and Diluted Income (Loss) per Share

Earnings or loss per share (“EPS”) is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted EPS is computed by dividing net income (loss) by the weighted-average of all potentially dilutive shares of common stock that were outstanding during the periods presented.

The treasury stock method is used in calculating diluted EPS for potentially dilutive stock options and share purchase warrants, which assumes that any proceeds received from the exercise of in-the-money stock options and share purchase warrants, would be used to purchase common shares at the average market price for the period.

EPS for convertible debt is calculated under the “if-converted” method. Under the if-converted method, EPS is calculated as the more dilutive of EPS (i) including all interest (both cash interest and non-cash discount amortization) and excluding all shares underlying the convertible debt or; (ii) excluding all interest and costs directly related to the convertible debt (both cash interest and non-cash discount amortization) and including all shares underlying the convertible debt.

The basic and diluted loss per share for the three months ended June 30, 2016 and 2015 were calculated as follows:

		Three Months Ended
		June 30, 2016			June 30, 2015
		$			$


Net loss, basic and diluted		(3,084,424	)		(2,554,367	)
Denominator
Basic and dilutive weighted average common shares outstanding		81,003,020			63,722,378

Basic and dilutive net loss per share	$	(0.04	)	$	(0.04	)

The following outstanding securities for the three months ended June 30, 2016 and 2015 have been excluded from the computation of diluted weighted shares outstanding, as they would have been anti-dilutive:

	Three Months	Three Months
	Ended	Ended
	June 30, 2016	June 30, 2015
Options outstanding	6,520,000	4,920,000
Warrants outstanding	10,182,629	9,068,741
Total	16,702,629	13,988,741

Recent Accounting Pronouncements

In March 2016, the FASB issued ASU 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting . The amendments in this update change existing guidance related to accounting for employee share-based payments affecting the income tax consequences of awards, classification of awards as equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within those annual periods, with early adoption permitted. The Company is currently evaluating the potential impact of the adoption of this standard.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) . The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the consolidated balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the consolidated income statement. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the potential impact of the adoption of this standard.

In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities . The amendments in this update revise the accounting related to the classification and measurement of investments in equity securities and the presentation of certain fair value changes for financial liabilities measured at fair value. The amendments are effective for annual reporting periods after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable) and to provide related footnote disclosures. The ASU provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. The ASU is effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016, which for the Company is April 1, 2017. Early adoption is permitted. The adoption of this standard will not have a material impact on the Company’s financial position or results of operations.

The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties , is applicable to entities that have not commenced planned principal operations. The central feature of the guidance on disclosure requirements is that required disclosures are limited to matters significant to a particular entity. The disclosures focus primarily on risks and uncertainties that could significantly affect the amounts reported in the financial statements in the near term or the near-term functioning of the reporting entity.

COMMON STOCK AND WARRANTS

3 Months Ended

Jun. 30, 2016

COMMON STOCK AND WARRANTS [Text Block]

3.	COMMON STOCK AND WARRANTS

As of June 30, 2016, the Company’s certificate of incorporation authorized the Company to issue unlimited Class A common shares without par value. Each Class A common share is entitled to have the right to vote at any shareholder meeting on the basis of one vote per share. Each Class A share held entitles the holder to receive dividends as declared by the directors. No dividends have been declared through June 30, 2016. In the event of the liquidation, dissolution or winding-up of the Company other distribution of assets of the Company among its shareholders for the purposes of winding-up its affairs or upon a reduction of capital the holders of the Class A common shares shall, share equally, share for share, in the remaining assets and property of the Company.

The Company is subject to a stockholders agreement, which places certain restrictions on the Company’s stock and its stockholders. These restrictions include approvals prior to sale or transfer of stock, a right of first refusal to purchase stock held by the Company and a secondary right of refusal to stockholders, right of co-sale whereby certain stockholders may be enabled to participate in a sale of other stockholders to obtain the same price, term and conditions on a pro-rata basis, rights of first offer of new security issuances to current stockholders on a pro-rata basis and certain other restrictions.

On April 30, 2015, the Company closed a non-brokered private placement (the “First Financing”) raising gross proceeds of $1,825,937 by the issuance of 849,273 units (each a “First Financing Unit”) at a price of $2.15 per First Financing Unit. Each First Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “First Financing Warrant”). Each whole First Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the Financing. The Company paid a cash finder’s fee of $84,074 in connection with this First Financing, as well as 27,396 finder’s warrants (the “First Financing Finder’s Warrants”). Each First Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the First Financing.

On June 26, 2015, the Company closed a non-brokered private placement (the “Second Financing”) raising gross proceeds of $721,243 by the issuance of 335,463 units (each a “Second Financing Unit”) at a price of $2.15 per Second Financing Unit. Each Second Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “Second Financing Warrant”). Each whole Second Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the Second Financing. The Company paid a cash finder’s fee of $40,803 in connection with this Second Financing, as well as 18,978 finder’s warrants (the “Second Financing Finder’s Warrants”). Each Second Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $2.15 per share for a period of sixty (60) months from the closing date of the Second Financing.

On July 17, 2015, the Company closed a non-brokered private placement (the “Third Financing”) raising gross proceeds of $270,375 by the issuance of 125,756 units (each a “Third Financing Unit”) at a price of $2.15 per Third Financing Unit. Each Third Financing Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a “Third Financing Warrant”). Each whole Third Financing Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $3.00 per share for a period of thirty-six (36) months from the closing date of the Third Financing. The Company paid a cash finder’s fee of $16,223 in connection with this Third Financing, as well as 7,545 finder’s warrants (the “Third Financing Finder’s Warrants”). Each Third Financing Finder’s Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of $2.15 per share for a period of sixty (60) months from the closing date of the Third Financing.

On November 10, 2015, upon conversion of the $2.0 million Note, the Company issued 2,083,333 shares of common stock at a price of $0.96 per share and 1,041,667 warrants exercisable at $1.44 for a period of three years from the date of issuance.

On December 29, 2015, the Company drew down the remaining $5.0 million commitment through the issuance of 5,555,556 shares of common stock at a price of $0.90 per share and 2,777,778 warrants exercisable at $1.35 for a period of three years from the date of issuance. The shares of common stock and the warrants were issued on January 7, 2016.

On April 18, 2016, the Company closed its short form prospectus offering in Canada and a concurrent U.S. private placement (the "Offering") of units (the "Units") with gross proceeds to the Company of CAD $9,215,000 through the issuance of Units at a price of CAD $1.00 per Unit. Each Unit consists of one Class A common share in the capital of the Company (a “Common Share”) and one half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to acquire one additional Common Share at an exercise price of CAD $1.50 on or before April 18, 2019. Mackie Research Capital Corporation (the "Agent") acted as agent and sole bookrunner in connection with the Offering. The Company paid the Agent a cash commission of CAD $436,050 and has granted to the Agent compensation options exercisable to purchase 436,050 Units at an exercise price of CAD $1.00 per Unit for a period of 24 months from the closing of the Offering. The Company incurred other cash issuance costs of USD $1,238,566 related to this offering.

On May 2, 2016, the Company closed the sale of the additional units issued pursuant to the exercise of the over-allotment option (“Over-Allotment Option”) granted to the Agent in connection with the Offering. The Offering was made pursuant to a short form prospectus filed with the securities regulatory authorities in each of the provinces of Canada, except Québec. Pursuant to the exercise of the Over-Allotment Option, the Company issued an additional 1,090,125 Units (the "Over-Allotment Units") at a price of CAD $1.00 per Over-Allotment Unit for additional gross proceeds to the Company of CAD $1,090,125, bringing the total aggregate gross proceeds to the Company under the Offering to CAD $10,305,125. Each Over-Allotment Unit consists of one Class A common share in the capital of the Company (an “Over-Allotment Common Share”) and one half of one Common Share purchase warrant (each whole warrant, an “Over-Allotment Warrant”). Each Over-Allotment Warrant entitles the holder thereof to acquire one additional Over-Allotment Common Share at an exercise price of CAD $1.50 on or before April 18, 2019. In connection with the closing of the Over-Allotment Option, the Company paid the Agent a cash commission of CAD $65,408 and granted to the Agent compensation options exercisable to purchase 65,407 Over-Allotment Units at an exercise price of CAD $1.00 per Over-Allotment Unit for a period of 24 months from the closing of the Offering.

The warrants issued in each of the April 18, 2016 and May 2, 2016 closings are classified within equity. The proceeds from the Offering were allocated on a relative fair value basis between the Class A common shares and the warrants issued. The compensation options are accounted for as warrants. These warrants represent additional share issuance costs and are recorded within equity at their fair value. The fair value of both the warrants and the compensation options was determined using a Black-Scholes option pricing model.

The fair value of the warrants granted during the three months ended June 30, 2016 was estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	June 30, 2016

Stock price	$1.09 CAD
Exercise Price	$1.50 CAD
Expected life	3.0 years
Expected volatility	83.83%
Risk – free interest rate	0.60%
Dividend rate	0.00%

The fair value of the compensation options granted during the three months ended June 30, 2016 was estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	June 30, 2016

Stock price	$1.36 CAD
Exercise Price	$1.00 CAD
Expected life	2.0 years
Expected volatility	126.76%
Risk – free interest rate	0.61%
Dividend rate	0.00%

On June 6, 2016, the Company announced that it received proceeds of CAD $1,825,600 from the exercise of 1,825,600 outstanding warrants which were issued in connection with the Company’s private placement of subscription receipts that closed on May 30, 2014. The remaining 6,604,400 warrants issued in this offering expired unexercised.

Pursuant to the guidance of ASC 815 Derivatives and Hedging , the Company determined that all of the warrants issued during the year ended March 31, 2016 as described above are required to be accounted for as liabilities because they are considered not to be indexed to the Company’s stock due to the exercise price being denominated in a currency other than the Company’s functional currency. Consequently, the Company determined the fair value of each warrant issuance using the Black-Scholes option pricing model, with the remainder of the proceeds allocated to the common shares.

The warrants having an exercise price denominated in a currency other than the functional currency of the Company that are required to be accounted for as liabilities are summarized as follows for the three months ended June 30, 2016 and 2015:

	Three months ended June 30, 2016 $	Three months ended June 30, 2015 $

Fair value of warrants, beginning of the period	1,204,581	-
Issuance	-	495,954
Change in fair value of warrants during the period	909,926	(86,538)
Fair value of warrants, end of the period	2,114,507	409,416

The warrants are required to be re-valued with the change in fair value of the liability recorded as a gain or loss in the change of fair value of derivative liability, included in other income (expense) in the Company’s consolidated statements of operations and comprehensive loss at the end of each reporting period. The fair value of the warrants will continue to be classified as a liability until such time as they are exercised, expire or there is an amendment to the respective agreements that renders these financial instruments to be no longer classified as a liability.

The fair value of liability classified warrants outstanding as of June 30, 2016 were estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	June 30, 2016
Stock price	$1.11
Exercise Price	$1.62
Expected life	2.40 years
Expected volatility	87.06%
Risk – free interest rate	0.62%
Dividend rate	0.00%

The continuity of warrants for the three months ended June 30, 2016 is as follows:

	Number of warrants				Weighted Average Exercise Price
	CAD		US		CAD	US
Balance, March 31, 2016	8,430,000		4,528,609	$	1.00	1.62
Granted	5,654,020		-	$	1.46	-
Granted (Agent Compensation)	501,457		-		1.00	-
Expired	(6,604,400	)	-	$	1.00	-
Exercised	(1,825,600	)	-	$	1.00	-
Balance, June 30, 2016	5,654,020		4,528,609	$	1.46	1.62

The warrants outstanding and exercisable at June 30, 2016 are as follows:


Number of warrants outstanding	Exercise Price	Expiry Date
452,032	US $3.00	April 30, 2018
167,731	US $3.00	June 26, 2018
18,978	US $2.15	June 26, 2020
62,878	US $3.00	July 17, 2018
7,545	US $2.15	July 17, 2020
1,041,667	US $1.44	November 10, 2018
2,777,778	US $1.35	December 29, 2018
5,152,563	CAD $1.50	April 18, 2019
501,457	CAD $1.00	April 18, 2018

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

SHARE BASED PAYMENTS

3 Months Ended

Jun. 30, 2016

SHARE BASED PAYMENTS [Text Block]

4.	SHARE BASED PAYMENTS

On June 18, 2014, the Company’s Board of Directors authorized and approved the adoption of the 2014 Plan (“2014 Plan”), under which an aggregate of 12,108,016 shares of common stock may be issued. Pursuant to the terms of the 2014 Plan, the Company is authorized to grant stock options, as well as awards of stock appreciation rights, restricted stock, unrestricted shares, restricted stock units and deferred stock units. These awards may be granted to directors, officers, employees and eligible consultants. Vesting and the term of an option is determined at the discretion of the Board of Directors of the Company. At June 30, 2016, there were 5,588,016 common shares remaining available for grant under the 2014 Plan.

The continuity of stock options for the year ended June 30, 2016 is as follows:

				Weighted
				Average		Aggregate
				Exercise Price		Intrinsic Value
	Number			(CAD)		(CAD)

Balance outstanding at March 31, 2016	6,675,360		$	1.08	$	1,580,883
Forfeited	(31,250	)		0.60		-
Cancelled	(124,110	)		0.60		-

Balance outstanding at June 30, 2016	6,520,000		$	1.09	$	4,127,200

Balance exercisable at June 30, 2016	5,510,835		$	1.10	$	3,574,184

The options outstanding and exercisable at June 30, 2016 are as follows:

		Options
		outstanding
		remaining					Number of
Number of		contractual life		Exercise		Grant date fair	options
options	Expiry date	(years)		Price (CAD)		value (CAD)	exercisable

3,520,000	June 18, 2019	2.97	$	0.60	$	0.26	3,520,000
100,000	July 14, 2017	1.04	$	2.52	$	1.05	100,000
450,000	December 8, 2019	3.44	$	2.92	$	1.65	450,000
100,000	December 8, 2019	3.44	$	2.92	$	1.31	66,667
400,000	December 8, 2019	3.44	$	2.96	$	1.29	400,000
100,000	March 16, 2020	3.71	$	3.20	$	1.42	66,667
50,000	August 15, 2020	4.13	$	0.98	$	0.39	16,667
750,000	October 21, 2020	4.31	$	0.87	$	0.36	187,500
550,000	October 28, 2020	4.33	$	0.84	$	0.44	550,000
400,000	October 28,2020	4.33	$	0.84	$	0.36	120,000
100,000	December 31, 2020	4.51	$	1.24	$	0.50	33,334


6,520,000							5,510,835

Included in the table above are non-employee awards that are subject to remeasurement each reporting period until vested. As a result, the grant date fair value is not representative of the total expense that will be recorded for these awards. As of June 30, 2016, the unrecognized compensation cost related to non-vested stock options outstanding, was $240,993 to be recognized over a weighted-average remaining vesting period of approximately 2.02 years. The Company recognizes compensation expense for only the portion of awards that are expected to vest. For the three months ended June 30, 2016 and 2015, the Company applied an expected forfeiture rate of 0% based on its historical experience.

Non-Employee Stock Options

In accordance with the guidance of ASC 815-40-15, stock options awarded to non-employees that are performing services for Neuro are required to be accounted for as derivative liabilities once the services have been performed and the options have vested because they are considered not to be indexed to the Company’s stock due to their exercise price being denominated in a currency other than Neuro’s functional currency. Stock options awarded to non-employees that are not vested are re-measured at their respective fair values at each reporting period and accounted for as equity awards until the terms associated with their vesting requirements have been met. The changes in fair value of the unvested non-employee awards are reflected in their respective operating expense classification in the Company’s consolidated statements of operations and comprehensive loss.

The non-employee stock options that are required to be accounted for as liabilities are summarized as follows for the three months ended June 30, 2016 and 2015:

	Three months ended June 30, 2016 $	Three months ended June 30, 2015 $

Fair value of non-employee options, beginning of the period	521,179	1,581,444
Issuance	-	-
Reallocation of vested non-employee options	268,135	690,885
Change in fair value of non-employee stock options during the period	399,456	(426,246)

Fair value of non-employee options, end of the period	1,188,770	1,846,083

The non-employee options that have vested are required to be re-valued with the change in fair value of the liability recorded as a gain or loss on the change of fair value of derivative liability and included in other items in the Company’s consolidated statements of operations and comprehensive loss at the end of each reporting period. The fair value of the options will continue to be classified as a liability until such time as they are exercised, expire or there is an amendment to the respective agreements that renders these financial instruments to be no longer classified as a liability.

The fair value of non-employee liability classified awards at June 30, 2016 and 2015 was estimated using the Black-Scholes option pricing model with the following weighted-average assumptions:

	June 30, 2016	June 30, 2015

Stock price	$1.46 CAD	$2.50 CAD
Exercise Price	$1.23 CAD	$1.52 CAD
Expected life	3.10 years	3.98 years
Expected volatility	83.83%	67.85%
Risk – free interest rate	0.52%	1.31%
Dividend rate	0.00%	0.00%

Share-based payments are classified in the Company’s statements of operations and comprehensive loss as follows for the three months ended June 30, 2016 and 2015:

	Three months ended June 30, 2016 $	Three months ended June 30, 2015 $

General and administrative	169,798	325,990
Research and development	106,932	134,148

	276,730	460,138

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Jun. 30, 2016

COMMITMENTS AND CONTINGENCIES [Text Block]

5.	COMMITMENTS AND CONTINGENCIES

(a)	On January 22, 2013, the Company entered into a license agreement with ANR for an exclusive right on ANR’s patent pending technology, claims and knowhow. In addition to the issuance of 16,035,026 shares, the Company agreed to pay a 4% royalty on net revenue on the sales of devices covered by the patent-pending technology and services related to the therapy or use of devices covered by the patent-pending technology. The Company has not made any royalty payments to date under this agreement.

(b)	On March 7, 2014, the Company entered into a commercial development-to-supply program with Ximedica, LLC (“Ximedica”) where Ximedica will design, develop and produce PoNS™ product solution suitable for clinical trial and commercial sale. Under the program, the Company is responsible for ensuring the device is in compliance with relevant laws and regulations. The agreed budget for phase 1B of development is $499,000 ; phase 2 is $1,065,000 ; Phase 3 and 4 is $1,389,000 and 2nd software development cycle is $586,000, of which $5,414,111 was expensed as research and development since inception to June 30, 2016.


	Invoices are to be issued monthly for work in progress. The Company can cancel the project at any time with a written notice at least 30 days prior to the intended date of cancellation. The Company recorded a prepaid expense of $274,000 to Ximedica for the upcoming clinical build of the PoNS™ device. As of June 30, 2016, the Company has expensed $154,626 of the $274,000 prepayment. As of June 30, 2016, the Company had also recorded a $300,000 project initiation deposit which will be applied once the development-to-supply program has been completed. During the three months ended June 30, 2016 and 2015, the Company incurred R&D charges of $222,743 and $818,020 pursuant to this agreement.

(c)	On January 27, 2015, the Company received a demand letter containing allegations that it had entered into a consulting arrangement with the complainants and breached certain of its terms, and used certain intellectual property in the form of business and marketing plans allegedly prepared by the complainants, and seeking damages. On May 7, 2015, Mr. Rainier Maas and Dr. Jochen Scheld filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania seeking monetary damages in excess of $225,000. On December 2, 2015 the Company entered into a settlement agreement with the plaintiffs for an amount of € 57,000 which was subsequently paid on January 12, 2016. The parties have since executed the settlement agreement for the aforementioned amount and the case has been dismissed without prejudice.

(d)	On January 5, 2015, Wicab Inc. (“Wicab”) filed a complaint against the Company, NHC, its director Mitchell Tyler, and its former director Yuri Danilov, and ANR in the U.S. District Court for the Western District of Wisconsin. The complaint contained various state and common law claims arising from Messrs. Danilov’s and Tyler’s prior employment with Wicab and the Company’s two issued patents for the PoNS™ device. The complaint alleged, among other things, that following their departure from Wicab, Messrs. Danilov and Tyler knowingly filed patent applications for and used ideas and inventions developed at Wicab in violation of various non-competition and confidentiality agreements, and that the Company’s two issued patents are therefore rightfully the property of Wicab. The complaint sought an unspecified amount of monetary damages, an injunction preventing the Company from using the ideas and inventions in the two patents, an order transferring ownership of the patents from the Company to Wicab, and recovery of costs and attorneys’ fees. The complaint was voluntarily dismissed without prejudice on January 14, 2015.

	On October 12, 2015, the Company received a letter from Wicab alleging that the two issued patents were invalid in view of prior art cited in the letter, including scientific publications and patent applications, and that Paul Bach-y-Rita, Wicab’s founder, should have been named as an inventor on these two issued patents. Wicab indicated in the letter that it may file reexamination or inter partes review proceedings with the U.S. Patent Office to attempt to invalidate the claims in the two issued patents. Wicab also stated that it would consider an unspecified “business solution” to resolve this matter. On December 10, 2015, representatives of each of the Company and Wicab met to discuss the parameters of a potential settlement. There can be no guarantee that a settlement will be reached. In the event that a settlement with Wicab is not reached, Wicab may file reexamination or inter partes review proceedings with the U.S. Patent Office to challenge the validity of the two issued patents. If the Company receives an adverse decision from the U.S. Patent Office in connection with these proceedings, some or all of the claims in the two patents may be invalidated or otherwise impaired, which could prevent the Company from bringing an infringement suit against a future competitor for making use of the PoNS™ technology for neurorehabilitation, and could have a material adverse effect on the Company’s business, operating results and financial condition. Wicab may also take other actions against the Company, its assets, intellectual property rights, officers, directors, employees, agents or other persons or entities which may also have a material effect on the Company’s business, operating results and financial condition. The Company believes that the possibility of an economic outlay is remote.

(e)	Under the Company’s Asset Purchase Agreement with A&B, if the Company fails to obtain FDA clearance for commercialization of or otherwise fails to ensure that the PoNS™ device is available for purchase by the U.S. Government by December 31, 2017, the Company is subject to a US$2,000,000 contract penalty payable to A&B, unless the Company receives an exemption for the requirement of FDA clearance from the US Army Medical Material Agency. The Company has determined that the possibility of an economic outlay under this contractual penalty is remote.

(f)	In November 2014, the Company signed a development and distribution agreement with the Altair company in Russia to apply for registration and distribute the PoNS™ device in the territories of the former Soviet Union. However, there is no assurance that such commercialization will occur.

RELATED PARTY TRANSACTIONS

3 Months Ended

Jun. 30, 2016

RELATED PARTY TRANSACTIONS [Text Block]

6.	RELATED PARTY TRANSACTIONS

During the three months ended June 30, 2016 and 2015, the Company paid $29,107 and $40,160 in consulting fees to directors of the Company. This expense was included in research and development expense. At June 30, 2016 and 2015, the Company owed $Nil and $24,418 to a director for consulting services.

During the three months ended June 30, 2016 and 2015, an expense of $106,932 and a benefit of $15,750 was included in research & development expense as the fair value of stock-based compensation attributed to the options granted to two directors and a consultant for consulting services rendered with respect to the design and development of the PoNS™ device.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

SOLE-SOURCE COST-SHARING AGREEMENT

3 Months Ended

Jun. 30, 2016

SOLE-SOURCE COST-SHARING AGREEMENT [Text Block]

7.	SOLE-SOURCE COST-SHARING AGREEMENT

During the fiscal year ended March 31, 2016, the Company entered into a sole source cost sharing contract executed with the USAMRMC. Under the terms of the contract, the USAMRMC will reimburse the Company up to a maximum of $2,996,244 representing approximately 62% of the Company’s estimated costs for the registrational trial (“the trial”) investigating the safety and effectiveness of the portable neuromodulation stimulator for mild to moderate traumatic brain injury. The trial expires on December 31, 2016 however the Company is working with the USAMRMC to extend the contract into 2017 based on the current trial forecast timelines. As of June 30, 2016, the Company has received a total of $1,628,627 in respect of expenses reimbursed. All reimbursement amounts received are credited directly to the accounts in which the original expense is recorded, including research and development, wages and salaries, and legal expenses.

Under the terms of the agreement, the USAMRMC may terminate their obligation at any time with 30 days written notice.

SUPPLEMENTAL CASH FLOW INFORMATION

3 Months Ended

Jun. 30, 2016

SUPPLEMENTAL CASH FLOW INFORMATION [Text Block]

8.	SUPPLEMENTAL CASH FLOW INFORMATION

Investing and financing activities that do not have a direct impact on current cash flows are excluded from the consolidated statements of cash flows.

During the three months ended June 30, 2016, the Company had the following non-cash financing transactions:

Fair value of warrants issued to agent for services provided in conjunction with the Offering was $366,271.

During the three months ended June 30, 2015, the Company had the following non-cash financing transactions:

Fair value of liability classified warrants issued in conjunction with private placement offerings was $495,954

SUBSEQUENT EVENTS

3 Months Ended

Jun. 30, 2016

SUBSEQUENT EVENTS [Text Block]

9.	SUBSEQUENT EVENTS

On July 7, 2016, 750 Agent Compensation options issued pursuant to the Offering were exercised for gross proceeds of CAD $750.

On July 13, 2016 the Securities and Exchange Commission (“SEC”) declared effective the Company’s registration statement on Form S-1 relating to the resale of up to 11,953,115 shares of the Company’s Class A common stock, without par value (the “Common Shares), 5,074,560 warrants to purchase shares of the Company’s Class A common stock at an exercise price of CAD$1.50 per share (US$1.15 per share at the noon exchange rate as published by the Bank of Canada on July 12, 2016) (the “Warrants”), and 5,074,560 shares of our Class A common stock issuable upon the exercise of the Warrants held by certain security holders of the Company named in the registration statement (the “Warrant Shares”, and together with the Common Shares and the Warrants, the “Securities”).

The registration statement, while effective, allows the selling security holders named in the registration statement to publicly resell the Securities. Helius will not receive any proceeds from the sale of the Securities by the selling security holders. Upon the cash exercise of the Warrants, Helius will receive the exercise price of the Warrants.

On August 4, 2016, the Board of Director selected Thomas E. Griffin to the Board. Mr. Griffin was also appointed as the Chairman to Audit Committee.

Mr. Griffin has not participated in any transactions with the Company, nor are there currently any proposed transactions, requiring disclosure pursuant to Item 404(a) of Regulation S-K.

As a member of the Board of Directors, Mr. Griffin will be eligible to receive non-employee director compensation consistent with that provided to other non-employee directors: 100,000 stock options ( 75,000 as a Board Member and 25,000 as a member of the Audit Committee). The options will vest as follows: 25% upon date of issuance, 25% at one year anniversary of issuance date and 50% at year 2 anniversary of issuance date. The strike price will be set at the close of the market on the date of issuance.

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Jun. 30, 2016

Use of Estimates [Policy Text Block]

Use of Estimates

Principles of Consolidation [Policy Text Block]

Principles of Consolidation

Cash and Cash Equivalents [Policy Text Block]

Cash and Cash Equivalents

Cash and cash equivalents comprise cash at banks and on hand, and short-term highly liquid investments that have an insignificant interest rate risk and an original maturity of 3 months or less.

Concentrations of Credit Risk [Policy Text Block]

Concentrations of Credit Risk

Receivables [Policy Text Block]

Receivables

Stock-Based Compensation [Policy Text Block]

Stock-Based Compensation

The Company accounts for all stock-based payments and awards under the fair value based method. The Company recognizes its stock-based compensation using the straight line method.

Foreign Exchange [Policy Text Block]

Foreign Exchange

Income Taxes [Policy Text Block]

Income Taxes

Research and Development Expenses [Policy Text Block]

Research and Development Expenses

Segment Information [Policy Text Block]

Segment Information

Derivative Liabilities [Policy Text Block]

Derivative Liabilities

Fair Value Measurements [Policy Text Block]

Fair Value Measurements

Level 1 – Quoted prices in active markets for identical assets or liabilities;

Basic and Diluted Income (Loss) per Share [Policy Text Block]

Basic and Diluted Income (Loss) per Share

The basic and diluted loss per share for the three months ended June 30, 2016 and 2015 were calculated as follows:

		Three Months Ended
		June 30, 2016			June 30, 2015
		$			$


Net loss, basic and diluted		(3,084,424	)		(2,554,367	)
Denominator
Basic and dilutive weighted average common shares outstanding		81,003,020			63,722,378

Basic and dilutive net loss per share	$	(0.04	)	$	(0.04	)

	Three Months	Three Months
	Ended	Ended
	June 30, 2016	June 30, 2015
Options outstanding	6,520,000	4,920,000
Warrants outstanding	10,182,629	9,068,741
Total	16,702,629	13,988,741

Recent Accounting Pronouncements [Policy Text Block]

Recent Accounting Pronouncements

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Tables)

3 Months Ended

Jun. 30, 2016

Schedule of Revision on Condensed Consolidated Statements of Operations and Comprehensive Loss [Table Text Block]

		Three Months Ended June 30, 2015
		As Previously						As
		Reported			Adjustment			Revised
Additional paid-in capital	$	2,053,907		$	149,898		$	2,203,805
Research & development	$	1,370,926		$	149,898		$	1,520,824
Loss from operations	$	(2,835,775	)	$	(149,898	)	$	(2,985,673	)
Net loss	$	(2,404,469	)	$	(149,898	)	$	(2,554,367	)
Earnings per share
Basic and Diluted	$	(0.04	)	$	-		$	(0.04	)
Total comprehensive loss	$	(2,363,843	)	$	(149,898	)	$	(2,513,741	)

SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Jun. 30, 2016

Fair Value, by Balance Sheet Grouping [Table Text Block]

	Fair Value	Level 1	Level 2	Level 3
June 30, 2016

Liabilities:
Non-employee options	1,188,770	-	-	1,188,770
Warrants	2,114,507	-	-	2,114,507

March 31, 2016

Liabilities:
Non-employee options	521,179	-	-	521,179
Warrants	1,204,581	-	-	1,204,581

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

		Three Months Ended
		June 30, 2016			June 30, 2015
		$			$


Net loss, basic and diluted		(3,084,424	)		(2,554,367	)
Denominator
Basic and dilutive weighted average common shares outstanding		81,003,020			63,722,378

Basic and dilutive net loss per share	$	(0.04	)	$	(0.04	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three Months	Three Months
	Ended	Ended
	June 30, 2016	June 30, 2015
Options outstanding	6,520,000	4,920,000
Warrants outstanding	10,182,629	9,068,741
Total	16,702,629	13,988,741

COMMON STOCK AND WARRANTS (Tables)

3 Months Ended

Jun. 30, 2016

Schedule of Stockholders' Equity Note, Warrants or Rights, Valuation Assumptions [Table Text Block]

	June 30, 2016

Stock price	$1.09 CAD
Exercise Price	$1.50 CAD
Expected life	3.0 years
Expected volatility	83.83%
Risk – free interest rate	0.60%
Dividend rate	0.00%

Schedule of Stockholders' Equity Note, Options, Valuation Assumptions [Table Text Block]

	June 30, 2016

Stock price	$1.36 CAD
Exercise Price	$1.00 CAD
Expected life	2.0 years
Expected volatility	126.76%
Risk – free interest rate	0.61%
Dividend rate	0.00%

Schedule of Warrants, Fair Values [Table Text Block]

	Three months ended June 30, 2016 $	Three months ended June 30, 2015 $

Fair value of warrants, beginning of the period	1,204,581	-
Issuance	-	495,954
Change in fair value of warrants during the period	909,926	(86,538)
Fair value of warrants, end of the period	2,114,507	409,416

Schedule of Stockholders' Equity Note, Liability Warrants, Valuation Assumptions [Table Text Block]

	June 30, 2016
Stock price	$1.11
Exercise Price	$1.62
Expected life	2.40 years
Expected volatility	87.06%
Risk – free interest rate	0.62%
Dividend rate	0.00%

Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block]

	Number of warrants				Weighted Average Exercise Price
	CAD		US		CAD	US
Balance, March 31, 2016	8,430,000		4,528,609	$	1.00	1.62
Granted	5,654,020		-	$	1.46	-
Granted (Agent Compensation)	501,457		-		1.00	-
Expired	(6,604,400	)	-	$	1.00	-
Exercised	(1,825,600	)	-	$	1.00	-
Balance, June 30, 2016	5,654,020		4,528,609	$	1.46	1.62

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]


Number of warrants outstanding	Exercise Price	Expiry Date
452,032	US $3.00	April 30, 2018
167,731	US $3.00	June 26, 2018
18,978	US $2.15	June 26, 2020
62,878	US $3.00	July 17, 2018
7,545	US $2.15	July 17, 2020
1,041,667	US $1.44	November 10, 2018
2,777,778	US $1.35	December 29, 2018
5,152,563	CAD $1.50	April 18, 2019
501,457	CAD $1.00	April 18, 2018

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

SHARE BASED PAYMENTS (Tables)

3 Months Ended

Jun. 30, 2016

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

				Weighted
				Average		Aggregate
				Exercise Price		Intrinsic Value
	Number			(CAD)		(CAD)

Balance outstanding at March 31, 2016	6,675,360		$	1.08	$	1,580,883
Forfeited	(31,250	)		0.60		-
Cancelled	(124,110	)		0.60		-

Balance outstanding at June 30, 2016	6,520,000		$	1.09	$	4,127,200

Balance exercisable at June 30, 2016	5,510,835		$	1.10	$	3,574,184

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

		Options
		outstanding
		remaining					Number of
Number of		contractual life		Exercise		Grant date fair	options
options	Expiry date	(years)		Price (CAD)		value (CAD)	exercisable

3,520,000	June 18, 2019	2.97	$	0.60	$	0.26	3,520,000
100,000	July 14, 2017	1.04	$	2.52	$	1.05	100,000
450,000	December 8, 2019	3.44	$	2.92	$	1.65	450,000
100,000	December 8, 2019	3.44	$	2.92	$	1.31	66,667
400,000	December 8, 2019	3.44	$	2.96	$	1.29	400,000
100,000	March 16, 2020	3.71	$	3.20	$	1.42	66,667
50,000	August 15, 2020	4.13	$	0.98	$	0.39	16,667
750,000	October 21, 2020	4.31	$	0.87	$	0.36	187,500
550,000	October 28, 2020	4.33	$	0.84	$	0.44	550,000
400,000	October 28,2020	4.33	$	0.84	$	0.36	120,000
100,000	December 31, 2020	4.51	$	1.24	$	0.50	33,334


6,520,000							5,510,835

Schedule of Non-Employee Share-based Compensation Arrangements Fair Values [Table Text Block]

	Three months ended June 30, 2016 $	Three months ended June 30, 2015 $

Fair value of non-employee options, beginning of the period	521,179	1,581,444
Issuance	-	-
Reallocation of vested non-employee options	268,135	690,885
Change in fair value of non-employee stock options during the period	399,456	(426,246)

Fair value of non-employee options, end of the period	1,188,770	1,846,083

Schedule Of Non-Employee Stock Options Awards Valuation Assumptions [Table Text Block]

	June 30, 2016	June 30, 2015

Stock price	$1.46 CAD	$2.50 CAD
Exercise Price	$1.23 CAD	$1.52 CAD
Expected life	3.10 years	3.98 years
Expected volatility	83.83%	67.85%
Risk – free interest rate	0.52%	1.31%
Dividend rate	0.00%	0.00%

Share-Based Payments Classified in the Companys Statement of Operations and Comprehensive Loss [Table Text Block]

	Three months ended June 30, 2016 $	Three months ended June 30, 2015 $

General and administrative	169,798	325,990
Research and development	106,932	134,148

	276,730	460,138

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Narrative) (Details)	3 Months Ended
	Jun. 30, 2016 USD ($)
Description Of Business And Basis Of Presentation 1	$ 3,084,424
Description Of Business And Basis Of Presentation 2	29,389,687
Description Of Business And Basis Of Presentation 3	$ 7,973,437

SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	3 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	Jun. 30, 2016 USD ($) mo
Significant Accounting Policies 1 \| mo	3
Significant Accounting Policies 2 \| $	$ 219,322
Significant Accounting Policies 3 \| $	$ 81,425
Significant Accounting Policies 4	50.00%
Significant Accounting Policies 5 \| mo	12

COMMON STOCK AND WARRANTS (Narrative) (Details) - 3 months ended Jun. 30, 2016	USD ($) mo $ / shares shares	CAD ($) mo shares
Common Stock And Warrants 1	$ 1,825,937
Common Stock And Warrants 2 \| shares	849,273	849,273
Common Stock And Warrants 3	$ 2.15
Common Stock And Warrants 4 \| $ / shares	$ 3.00
Common Stock And Warrants 5	$ 84,074
Common Stock And Warrants 6	27,396	27,396
Common Stock And Warrants 7 \| $ / shares	$ 3.00
Common Stock And Warrants 8	$ 721,243
Common Stock And Warrants 9 \| shares	335,463	335,463
Common Stock And Warrants 10	$ 2.15
Common Stock And Warrants 11 \| $ / shares	$ 3.00
Common Stock And Warrants 12	$ 40,803
Common Stock And Warrants 13	18,978	18,978
Common Stock And Warrants 14 \| $ / shares	$ 2.15
Common Stock And Warrants 15	$ 270,375
Common Stock And Warrants 16 \| shares	125,756	125,756
Common Stock And Warrants 17	$ 2.15
Common Stock And Warrants 18 \| $ / shares	$ 3.00
Common Stock And Warrants 19	$ 16,223
Common Stock And Warrants 20	7,545	7,545
Common Stock And Warrants 21 \| $ / shares	$ 2.15
Common Stock And Warrants 22	$ 2,000,000
Common Stock And Warrants 23 \| shares	2,083,333	2,083,333
Common Stock And Warrants 24 \| $ / shares	$ 0.96
Common Stock And Warrants 25 \| shares	1,041,667	1,041,667
Common Stock And Warrants 26	$ 1.44
Common Stock And Warrants 27	$ 5,000,000
Common Stock And Warrants 28 \| shares	5,555,556	5,555,556
Common Stock And Warrants 29 \| $ / shares	$ 0.90
Common Stock And Warrants 30 \| shares	2,777,778	2,777,778
Common Stock And Warrants 31	$ 1.35
Common Stock And Warrants 32		$ 9,215,000
Common Stock And Warrants 33		1.00
Common Stock And Warrants 34		1.50
Common Stock And Warrants 35		$ 436,050
Common Stock And Warrants 36	436,050	436,050
Common Stock And Warrants 37		$ 1.00
Common Stock And Warrants 38 \| mo	24	24
Common Stock And Warrants 39	$ 1,238,566
Common Stock And Warrants 40	1,090,125	1,090,125
Common Stock And Warrants 41		$ 1.00
Common Stock And Warrants 42		1,090,125
Common Stock And Warrants 43		10,305,125
Common Stock And Warrants 44		1.50
Common Stock And Warrants 45		$ 65,408
Common Stock And Warrants 46	65,407	65,407
Common Stock And Warrants 47		$ 1.00
Common Stock And Warrants 48 \| mo	24	24
Common Stock And Warrants 55		$ 1,825,600
Common Stock And Warrants 56 \| shares	1,825,600	1,825,600
Common Stock And Warrants 57 \| shares	6,604,400	6,604,400

SHARE BASED PAYMENTS (Narrative) (Details)	3 Months Ended
SHARE BASED PAYMENTS (Narrative) (Details)	Jun. 30, 2016 USD ($) yr shares
Share Based Payments 1	12,108,016
Share Based Payments 2	5,588,016
Share Based Payments 3 \| $	$ 240,993
Share Based Payments 4 \| yr	2.02
Share Based Payments 5	0.00%

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - 3 months ended Jun. 30, 2016	USD ($) d shares	EUR (€) d shares
Commitments And Contingencies 1 \| shares	16,035,026	16,035,026
Commitments And Contingencies 2	4.00%	4.00%
Commitments And Contingencies 3	$ 499,000
Commitments And Contingencies 4	$ 1,065,000
Commitments And Contingencies 5	4	4
Commitments And Contingencies 6	$ 1,389,000
Commitments And Contingencies 7	586,000
Commitments And Contingencies 8	$ 5,414,111
Commitments And Contingencies 9 \| d	30	30
Commitments And Contingencies 10	$ 274,000
Commitments And Contingencies 11	154,626
Commitments And Contingencies 12	274,000
Commitments And Contingencies 13	300,000
Commitments And Contingencies 14	222,743
Commitments And Contingencies 15	818,020
Commitments And Contingencies 16	225,000
Commitments And Contingencies 17 \| €		€ 57,000
Commitments And Contingencies 18	$ 2,000,000

RELATED PARTY TRANSACTIONS (Narrative) (Details)	3 Months Ended
RELATED PARTY TRANSACTIONS (Narrative) (Details)	Jun. 30, 2016 USD ($)
Related Party Transactions 1	$ 29,107
Related Party Transactions 2	40,160
Related Party Transactions 3	0
Related Party Transactions 4	24,418
Related Party Transactions 5	106,932
Related Party Transactions 6	$ 15,750

SOLE-SOURCE COST-SHARING AGREEMENT (Narrative) (Details)	3 Months Ended
	Jun. 30, 2016 USD ($) d
Sole-source Cost-sharing Agreement 1	$ 2,996,244
Sole-source Cost-sharing Agreement 2	62.00%
Sole-source Cost-sharing Agreement 3	$ 1,628,627
Sole-source Cost-sharing Agreement 4 \| d	30

SUPPLEMENTAL CASH FLOW INFORMATION (Narrative) (Details)	3 Months Ended
	Jun. 30, 2016 USD ($)
Supplemental Cash Flow Information 1	$ 366,271
Supplemental Cash Flow Information 2	$ 495,954

SUBSEQUENT EVENTS (Narrative) (Details) - 3 months ended Jun. 30, 2016	$ / shares	CAD ($) $ / shares shares
Subsequent Events 1		750
Subsequent Events 2 \| $		$ 750
Subsequent Events 1		11,953,115
Subsequent Events 2		5,074,560
Subsequent Events 3 \| $ / shares		$ 1.50
Subsequent Events 4 \| $ / shares	$ 1.15
Subsequent Events 5		5,074,560
Subsequent Events 6		100,000
Subsequent Events 7		75,000
Subsequent Events 8		25,000
Subsequent Events 9		25.00%
Subsequent Events 10		25.00%
Subsequent Events 11		50.00%
Subsequent Events 12		2

Schedule of Revision on Condensed Consolidated Statements of Operations and Comprehensive Loss (Details)	3 Months Ended
	Jun. 30, 2016 USD ($)
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 1	$ 2,053,907
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 2	149,898
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 3	2,203,805
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 1	1,370,926
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 2	149,898
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 3	1,520,824
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 4	(2,835,775)
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 5	(149,898)
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 6	(2,985,673)
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 7	(2,404,469)
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 8	(149,898)
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 9	$ (2,554,367)
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 10	(0.04)
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 11	$ 0
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 12	(0.04)
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 13	$ (2,363,843)
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 14	(149,898)
Description Of Business And Basis Of Presentation Schedule Of Revision On Condensed Consolidated Statements Of Operations And Comprehensive Loss 15	$ (2,513,741)

Fair Value, by Balance Sheet Grouping (Details)	3 Months Ended
Fair Value, by Balance Sheet Grouping (Details)	Jun. 30, 2016 USD ($)
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 1	$ 1,188,770
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 2	0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 3	0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 4	1,188,770
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 5	2,114,507
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 6	0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 7	0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 8	2,114,507
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 9	521,179
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 10	0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 11	0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 12	521,179
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 13	1,204,581
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 14	0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 15	0
Significant Accounting Policies Fair Value, By Balance Sheet Grouping 16	$ 1,204,581

Schedule of Earnings Per Share, Basic and Diluted (Details)	3 Months Ended
	Jun. 30, 2016 USD ($)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 1	$ (3,084,424)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 2	(2,554,367)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 7	81,003,020
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 8	$ 63,722,378
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 9	(0.04)
Significant Accounting Policies Schedule Of Earnings Per Share, Basic And Diluted 10	(0.04)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)	3 Months Ended
	Jun. 30, 2016 USD ($)
Significant Accounting Policies Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share 1	$ 6,520,000
Significant Accounting Policies Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share 2	4,920,000
Significant Accounting Policies Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share 3	10,182,629
Significant Accounting Policies Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share 4	9,068,741
Significant Accounting Policies Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share 5	16,702,629
Significant Accounting Policies Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share 6	$ 13,988,741

Schedule of Stockholders' Equity Note, Options, Valuation Assumptions (Details)	3 Months Ended
	Jun. 30, 2016 USD ($) yr
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Liability Warrants, Valuation Assumptions 1	$ 1.36
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Liability Warrants, Valuation Assumptions 2	$ 1.00
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Liability Warrants, Valuation Assumptions 3 \| yr	2
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Liability Warrants, Valuation Assumptions 4	126.76%
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Liability Warrants, Valuation Assumptions 5	0.61%
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Liability Warrants, Valuation Assumptions 6	0.00%

Schedule of Warrants, Fair Values (Details)	3 Months Ended
Schedule of Warrants, Fair Values (Details)	Jun. 30, 2016 USD ($)
Common Stock And Warrants Schedule Of Warrants, Fair Values 1	$ 1,204,581
Common Stock And Warrants Schedule Of Warrants, Fair Values 2	0
Common Stock And Warrants Schedule Of Warrants, Fair Values 3	0
Common Stock And Warrants Schedule Of Warrants, Fair Values 4	495,954
Common Stock And Warrants Schedule Of Warrants, Fair Values 5	909,926
Common Stock And Warrants Schedule Of Warrants, Fair Values 6	(86,538)
Common Stock And Warrants Schedule Of Warrants, Fair Values 7	2,114,507
Common Stock And Warrants Schedule Of Warrants, Fair Values 8	$ 409,416

Schedule of Stockholders' Equity Note, Liability Warrants, Valuation Assumptions (Details)	3 Months Ended
	Jun. 30, 2016 USD ($) yr
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 1	$ 1.11
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 2	$ 1.62
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 3 \| yr	2.4
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 4	87.06%
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 5	0.62%
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Valuation Assumptions 6	0.00%

Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details)	3 Months Ended
	Jun. 30, 2016 USD ($)
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1	$ 8,430,000
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 2	$ 4,528,609
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 3	1.00
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 4	1.62
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 5	$ 5,654,020
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 6	$ 0
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 7	1.46
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 8	$ 0
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 9	501,457
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 10	$ 0
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 11	1.00
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 12	$ 0
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 9	(6,604,400)
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 10	$ 0
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 11	1.00
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 16	$ 0
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 12	(1,825,600)
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 13	$ 0
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 14	1.00
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 15	$ 0
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 16	5,654,020
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 17	$ 4,528,609
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 18	1.46
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 19	1.62

Schedule of Stockholders' Equity Note, Warrants or Rights (Details) - 3 months ended Jun. 30, 2016	USD ($)	CAD ($)
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 1	$ 452,032
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 2	3.00
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 3	167,731
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 4	3.00
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 5	18,978
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 6	2.15
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 7	62,878
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 8	3.00
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 9	7,545
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 10	2.15
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 11	1,041,667
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 12	1.44
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 13	2,777,778
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 14	1.35
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 15	5,152,563
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 16		$ 1.50
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 17	$ 501,457
Common Stock And Warrants Schedule Of Stockholders' Equity Note, Warrants Or Rights 18		$ 1.00

Schedule of Share-based Compensation, Stock Options, Activity (Details)	3 Months Ended
	Jun. 30, 2016 USD ($)
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 1	$ 6,675,360
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 2	1.08
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 3	$ 1,580,883
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 4	$ (31,250)
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 5	0.60
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 6	$ 0
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 7	$ (124,110)
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 8	0.60
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 9	$ 0
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 10	$ 6,520,000
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 11	1.09
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 12	$ 4,127,200
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 13	$ 5,510,835
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 14	1.10
Share Based Payments Schedule Of Share-based Compensation, Stock Options, Activity 15	$ 3,574,184

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details)	3 Months Ended
	Jun. 30, 2016 USD ($)
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 1	$ 3,520,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 2	2.97
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 3	0.60
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 4	0.26
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 5	$ 3,520,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 6	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 7	1.04
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 8	2.52
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 9	1.05
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 10	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 11	$ 450,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 12	3.44
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 13	2.92
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 14	1.65
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 15	$ 450,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 16	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 17	3.44
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 18	2.92
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 19	1.31
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 20	$ 66,667
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 21	$ 400,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 22	3.44
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 23	2.96
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 24	1.29
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 25	$ 400,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 26	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 27	3.71
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 28	3.20
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 29	1.42
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 30	$ 66,667
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 31	$ 50,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 32	4.13
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 33	0.98
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 34	0.39
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 35	$ 16,667
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 36	$ 750,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 37	4.31
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 38	0.87
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 39	0.36
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 40	$ 187,500
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 41	$ 550,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 42	4.33
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 43	0.84
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 44	0.44
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 45	$ 550,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 46	$ 400,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 47	4.33
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 48	0.84
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 49	0.36
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 50	$ 120,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 51	$ 100,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 52	4.51
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 53	1.24
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 54	0.50
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 55	$ 33,334
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 56	6,520,000
Share Based Payments Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 57	$ 5,510,835

Schedule of Non-Employee Share-based Compensation Arrangements Fair Values (Details)	3 Months Ended
	Jun. 30, 2016 USD ($) shares
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 1	$ 521,179
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 2	1,581,444
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 3	$ 0
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 4 \| shares	0
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 5	$ 268,135
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 6	690,885
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 7	399,456
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 8	(426,246)
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 9	1,188,770
Share Based Payments Schedule Of Non-employee Share-based Compensation Arrangements Fair Values 10	$ 1,846,083

Schedule Of Non-Employee Stock Options Awards Valuation Assumptions (Details)	3 Months Ended
	Jun. 30, 2016 USD ($) yr
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 1	$ 1.46
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 2	2.50
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 3	1.23
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 4	$ 1.52
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 5 \| yr	3.1
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 6 \| yr	3.98
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 7	83.83%
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 8	67.85%
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 9	0.52%
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 10	1.31%
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 11	0.00%
Share Based Payments Schedule Of Non-employee Stock Options Awards Valuation Assumptions 12	0.00%

Share-Based Payments Classified in the Companys Statement of Operations and Comprehensive Loss (Details)	3 Months Ended
	Jun. 30, 2016 USD ($)
Share Based Payments Share-based Payments Classified In The Companys Statement Of Operations And Comprehensive Loss 1	$ 169,798
Share Based Payments Share-based Payments Classified In The Companys Statement Of Operations And Comprehensive Loss 2	325,990
Share Based Payments Share-based Payments Classified In The Companys Statement Of Operations And Comprehensive Loss 3	106,932
Share Based Payments Share-based Payments Classified In The Companys Statement Of Operations And Comprehensive Loss 4	134,148
Share Based Payments Share-based Payments Classified In The Companys Statement Of Operations And Comprehensive Loss 5	276,730
Share Based Payments Share-based Payments Classified In The Companys Statement Of Operations And Comprehensive Loss 6	$ 460,138